Allergy Immunotherapy Market Size & Share, by Treatment (Subcutaneous Immunotherapy, Sublingual Immunotherapy); Allergy Type (Allergic Rhinitis, Asthma, Allergic Conjunctivitis); Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3769
  • Published Date: Sep 26, 2023
  • Report Format: PDF, PPT

Companies Dominating the Allergic Immunotherapy Landscape

    • ALK
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Stallergenes Greer
    • Mylan N.V.
    • HAL Allergy B.V.
    • LETIPharma
    • AstraZeneca

Browse Key Market Insights with Data Illustration:


In The News

  • September 2023 - As a top provider of allergen immunotherapy (AIT), Stallergenes Greer has secured agreements with Nestlé on a global scale to use the oral immunotherapy drug Palforzia® to treat peanut allergy.Upon signing, the deal was finalized.
  • June 2023 – ALK recently released the preliminary findings from a Phase 3 pediatric clinical trial evaluating a sublingual allergy immunotherapy pill for the treatment of allergic rhinitis brought on by house dust mites (HDM). The HDM tablet is sold under the names MITICURETM in Japan, ODACTRA® in the USA, and ACARIZAX® in Europe and other international markets.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3769
  • Published Date: Sep 26, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing research and development activities and growing prevalence of allergies are some of the factors driving the market growth.

The market size of allergic immunotherapy is anticipated to attain a CAGR of 10% over the forecast period, i.e., 2024 – 2036.

The major players in the market are ALK, Stallergenes Greer, Mylan N.V., HAL Allergy B.V., LETIPharma, AstraZeneca, Takeda Pharmaceuticals Company Ltd, Chugai Pharmaceutical Co., Ltd, Eisai Co. Ltd, Astellas Pharma Inc. and others.

The subcutaneous immunotherapy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying